Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $39.00.

UPB has been the topic of several analyst reports. Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Finally, Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research report on Friday, March 27th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bain Capital Life Sciences Investors LLC increased its holdings in shares of Upstream Bio by 6.3% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock valued at $26,786,000 after purchasing an additional 144,216 shares during the period. Integral Health Asset Management LLC acquired a new position in Upstream Bio in the 3rd quarter valued at approximately $10,816,000. Geode Capital Management LLC lifted its position in Upstream Bio by 57.5% in the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after buying an additional 235,958 shares in the last quarter. Norges Bank purchased a new stake in Upstream Bio in the 2nd quarter worth approximately $10,650,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of Upstream Bio during the 2nd quarter valued at $89,000.

Upstream Bio Stock Up 3.4%

Shares of NASDAQ UPB opened at $9.31 on Friday. Upstream Bio has a 12 month low of $5.14 and a 12 month high of $33.68. The company has a market cap of $506.65 million, a price-to-earnings ratio of -3.49 and a beta of 1.78. The business has a fifty day simple moving average of $14.60 and a 200-day simple moving average of $21.19.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%.The company had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. As a group, sell-side analysts expect that Upstream Bio will post -4.3 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.